About the Journal
The Journal of Population Therapeutics and Clinical Pharmacology (ISSN 1198-581X, eISSN 1710-6222) previously published as The Canadian Journal of Clinical Pharmacology .
The Journal of Population Therapeutics and Clinical Pharmacology will consider for publication original research papers (clinical or epidemiological), review articles and case reports on all aspects of clinical pharmacology and therapeutics. Editorials/Commentaries or Letters to the Editor on ethical, policy or other contemporary issues are welcomed. Authors submitting adverse event reports for publications are requested to follow the guidelines developed by Kelly et al. Adverse Event Guidelines http://www.pharmacoepi.org/pub/1c2a2a00-2354-d714-51a7-1b28777098e8
Manuscripts are received with the understanding that they are submitted solely to the Journal of Population Therapeutics and Clinical Pharmacology, and that none of the material contained in the manuscript has been published previously or is under consideration for publication elsewhere, excluding abstracts. The publisher reserves copyright on all published material, and material may not be reproduced without the written permission of the publisher. Statements and opinions are the responsibility of the authors.
Scope of JPTCP
The Journal of Population Therapeutics and Clinical Pharmacology will consider for publication original research papers (clinical or epidemiological), review articles and case reports on all aspects of medicine, clinical pharmacology, and therapeutics.
Allergy and immunology; Anaesthesiology; Cardiology; Cardiothoracic surgery; Child and adolescent psychiatry; Clinical Nutrition, Clinical Pharmacology, Clinical Psychology; Dermatology; Emergency medicine; Endocrinology; Family Medicine; Gastroenterology; General Surgery; Geriatrics; Haematology; Infectious disease; Internal medicine; Medical biochemistry; Medical genetics; Neonatology; Nephrology; Neurology; Neurosurgery; Nuclear medicine; Obstetrics and gynecology; Occupational medicine; Ophthalmology; Orthopaedic surgery; Oral and maxillofacial surgery; Otorhinolaryngology; Palliative care; Pathology; Paediatrics; Physical medicine and rehabilitation; Pulmonology; Psychiatry; Public health; Radiology; Rheumatology; Sports medicine; Thoracic Surgery; Urology; Vascular surgery
The Journal of Population Therapeutics and Clinical Pharmacology is indexed with;
ESCI (Clarivate Analytics)
Each calendar year will have one volume. JPTCP publishes articles as soon as the final copy-edited version is approved by the authors rather than waiting for a collection of articles for a specific issue. Also, each article is published in its respective category (editorial, review, original, or commentary). As a result, the page numbers in the 'Table of Contents' displayed for each issue will reflect this rather than numerical order.
Author Processing Charges
There is no submission fee to JPTCP.
Please note that since May 1, 2019, the Journal of Population Therapeutics and Pharmacology (JPTCP) has charged an Author Processing Fee (APC) of $850. Articles will go through a thorough peer review process, benefit from high-quality editing, and will be posted on-line for greater exposure, within 60 days of acceptance. Articles are archived on the journal web site. All articles/information will also be included in the PubMed database, Emerging Sources Citation Index, Scopus, EMBASE. All articles will be assigned a unique DOI (Digital Object Identifier) through Cross Ref. An author’s ability to pay APCs is not a consideration in the decision of whether to publish.
The following questions and answers may help you to make an informed decision about the publishing fee.
What procedures have you implemented to ensure that the person who submits an article is aware of the publishing fee BEFORE completing the submission?
During the submission process, the person who submits the article has to tick a mandatory box confirming that he or she is aware of the publishing fee. This statement can be viewed under the ‘Submission Preparation Checklist’ .
Who is responsible for making or arranging the payment?
The person who submits the article is responsible for making or arranging the payment (for instance, via the institution) upon editorial acceptance of the manuscript. The invoice will be issued to the person who is identified as the author for correspondence in the manuscript.
When do I pay the publishing fee?
The publishing fee is payable after the editorial acceptance of an article. Upon editorial acceptance of an article, the submitting author and the author for correspondence will be notified that payment is due.
How do I pay the publishing fee?
There will be three options of payment: via direct bank transfer , by a credit card which is allowed to make international payments or via PayPal. The instructions for payment will be included in the invoice. No taxes are included in this charge. For any tax-related issues, please follow the regulations of your country.
Do I have to pay if my article is rejected?
If I withdraw my article, do I have to pay?
Authors can withdraw their articles at any stage. If a decision to withdraw is made by the author BEFORE the editorial acceptance of the article, then the authors do not have to pay. If a decision to withdraw is made by the author AFTER the editorial acceptance of an article, then the full fee of $850must be paid.
Why do I have to pay a publishing fee?
All articles published in JPTCP are open access and freely available online under Creative Commons Attribution 4.0 International (CC BY 4.0). This means anyone, anywhere in the world who has access to the internet can read your article without any restriction. The typical costs associated with the publication of articles could be grouped under three categories: technology, article processing, and post-publication activities.
Technology: Online presence requires a publication platform, hosting, necessary security features, and email services.
Article-processing: Receiving articles, a preliminary check of the manuscript to ensure adherence to guidelines, plagiarism check, communicating between authors/editors/reviewers, organizing peer review, receiving revised manuscripts, copyediting, implementing corrections by authors, typesetting, layout editing, proofreading, graphic design, assigning DOI to articles, reference checking, assigning DOI to references, indexing.
Post-publication activities: Conversion of articles to XML in accordance with PMC guidelines for PubMed indexing, article promotion, marketing, and continued online presence.
Do you have a publishing fee waiver policy?
Yes. We do have a waiver policy. For fee waiver write an email to email@example.com
Copyright and Licencing
Articles are published under a Creative Commons Attribution - Non Commercial 4.0 International License (CCBY-NC) Authors and users are free to copy and redistribute the material in any medium or format, with proper attribution, for non-commercial purposes. Authors retain copyright to their articles.
For more information about the Journal of Population Therapeutics and Clinical Pharmacology, please visit www.jptcp.com
Open Acess Policy
JPTCP provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
History of Journal
With its inception in 1994, The Canadian Journal of Clinical Pharmacology (now the Journal of Population Therapeutics and Clinical Pharmacology) filled an important gap in therapeutics research in Canada. For ten years, the success of CJCP was the result of the significant vision and efforts of the founding editor, Dr. Neil Shear.
In April 2004, The Canadian Journal of Clinical Pharmacology was innovative in becoming one of the first peer review, Medline indexed scientific journal in the field of therapeutics to be published on the Internet and available at no charge to the readers. This change reflected a vision and philosophy of the Canadian Society for Clinical Pharmacology that original information on rational therapeutics needs to be accessible to all health professionals prescribing or administering medications, as well as for all other stakeholders, including patients and families.
In the fall of 2007, another transformation took place. The Journal of Fetal Alcohol Syndrome International was amalgamated with the Canadian Journal of Clinical Pharmacology, Fetal Alcohol Research was created as a new section.
In 2010 the journal changed its name to the Journal of Population Therapeutics and Clinical Pharmacology. This change reflected the international sphere of the authors submitting publications to the journal and as well, the broad scope of topics covered in the journal. In addition to publishing articles in the field of clinical pharmacology, the journal has embraced articles related to pharmacoepidemiology, pharmacoeconomics, and drug policy, hence 'population therapeutics'.
Ownership and management:
Journal of Population Therapeutics and Clinical Pharmacology is published under the banner of Research Trentz, a privately-owned company. The administrative aspects of the journal are done through the coordinated effort of personnel located in India, Australia, Canada, and Singapore. Infrastructure for publication and technical support for online presence is provided by Open Journal Systems Company, Arizona, USA. Post-acceptance processing of articles is delegated to various companies. Services for doi and plagiarism check are provided by Crossref.
The views and opinions expressed in JPTCP are not necessarily those of the publisher, editor, or editorial board members. The Publisher, editors or the editorial board members cannot be held responsible for any errors or consequences arising from the use of the information contained in JPTCP. Publication of an advertisement does not constitute an endorsement of the product by the publisher, editor or the editorial board members.
While we make every effort to provide an uninterrupted online presence, we cannot guarantee this will be the case. The website is subject to interruptions. Also, we do not guarantee that website will be error-free. It is the responsibility of the user to make adequate provisions (up-to-date antivirus, security and intrusion prevention, and scanning software) for the protection of the device they are using.
We may provide links to external websites. These websites belong to third parties and we have no control over the reliability or stability of these links. While we verify them at the time of linking, we are unable to provide any warranty regarding the stability or availability of these links. Also, a link to an external site does not imply an endorsement of the views, information, or products provided or held by such websites.